PMID- 27042223
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160404
LR  - 20181113
IS  - 1759-7706 (Print)
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Linking)
VI  - 7
IP  - 2
DP  - 2016 Mar
TI  - Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in 
      non-small cell lung carcinoma patients in Korea: An observational study.
PG  - 207-14
LID - 10.1111/1759-7714.12315 [doi]
AB  - BACKGROUND: To investigate the efficacy, safety, and tolerability of weekly 
      docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in 
      Korea. METHODS: This prospective observational study included Korean advanced 
      NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who 
      received weekly monotherapy of docetaxel at a dose determined by the physician. 
      Efficacy measurements included tumor response rate, overall survival (OS), 
      progression-free survival, and one-year survival rate. Safety was analyzed 
      through recorded incidences of adverse events (AEs), serious adverse events 
      (SAEs), deaths, and other related safety parameters, along with their toxicity 
      grades. RESULTS: Of 274 patients analyzed, one patient achieved a complete 
      response and 42 partial responses; thus, the overall response rate was 15.7%. The 
      OS rate at baseline and at one-year follow-up was 38.3% and 33.8%, respectively. 
      AEs were reported in 229 (83.6%) patients. The most frequently reported 
      hematologic AE of grade >/=3 was a decrease in neutrophils, with 6.6% of the 
      patients developing neutropenia. In non-hematologic AEs of grade >/=3, the most 
      common were infection with unknown absolute neutrophil count and death not 
      associated with Common Terminology Criteria for Adverse Events (CTCAE) (4.7% 
      each). The most common SAE reported was death, not associated with CTCAE (7.3%). 
      CONCLUSIONS: In Korean patients, the weekly regimen of docetaxel monotherapy was 
      safe and efficacious against advanced NSCLC.
FAU - Lim, Sun Min
AU  - Lim SM
AD  - Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center 
      Seoul Korea; Division of Medical Oncology Department of Internal Medicine CHA 
      University Bundang Medical Center Seongnam Korea.
FAU - Park, Byeong Bae
AU  - Park BB
AD  - Hanyang University College of Medicine Division of Hematology-Oncology Department 
      of Internal Medicine Seoul Korea.
FAU - Park, Keun-Chil
AU  - Park KC
AD  - Samsung Medical Center Department of Hematology-Oncology Seoul Korea.
FAU - Kim, Hoon-Kyo
AU  - Kim HK
AD  - St. Vincent Hospital Department of Oncology Gyeonggi-do Korea.
FAU - Lee, Jong Seok
AU  - Lee JS
AD  - Seoul National University Bundang Hospital Gyeonggi-do Korea.
FAU - Bae, Sung Hwa
AU  - Bae SH
AD  - Daegu Catholic University Hospital Daegu Korea.
FAU - Lee, Seung-Sei
AU  - Lee SS
AD  - Kangbuk Samsung Medical Center Seoul Korea.
FAU - Kang, Jin-Hyoung
AU  - Kang JH
AD  - The Catholic University of Korea Seoul St. Mary's Hospital Seoul Korea.
FAU - Park, Se-Hoon
AU  - Park SH
AD  - Samsung Medical Center Department of Hematology-Oncology Seoul Korea.
FAU - Lee, Gyeong-Won
AU  - Lee GW
AD  - Gyeongsang National University Hospital Gyeongsang National University School of 
      Medicine Gyeongnam Korea.
FAU - Lee, Hyo-Rac
AU  - Lee HR
AD  - NHIC Ilsan Hospital Gyeonggi-do Korea.
FAU - Seo, Jae Hong
AU  - Seo JH
AD  - Korea University Guro Hospital Seoul Korea.
FAU - Kim, Yong Tae
AU  - Kim YT
AD  - NHIC Ilsan Hospital Gyeonggi-do Korea.
FAU - Yang, Sung Hyun
AU  - Yang SH
AD  - Korea Cancer Center Hospital Seoul Korea.
FAU - Kim, Joo-Hang
AU  - Kim JH
AD  - Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center 
      Seoul Korea.
LA  - eng
PT  - Journal Article
DEP - 20151101
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
PMC - PMC4773308
OTO - NOTNLM
OT  - Carcinoma
OT  - docetaxel
OT  - non-small cell lung cancer
OT  - safety
EDAT- 2016/04/05 06:00
MHDA- 2016/04/05 06:01
PMCR- 2016/03/01
CRDT- 2016/04/05 06:00
PHST- 2015/06/16 00:00 [received]
PHST- 2015/08/20 00:00 [accepted]
PHST- 2016/04/05 06:00 [entrez]
PHST- 2016/04/05 06:00 [pubmed]
PHST- 2016/04/05 06:01 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - TCA12315 [pii]
AID - 10.1111/1759-7714.12315 [doi]
PST - ppublish
SO  - Thorac Cancer. 2016 Mar;7(2):207-14. doi: 10.1111/1759-7714.12315. Epub 2015 Nov 
      1.